Skip to main content
SpringerLink
Log in

Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo

  • Original Papers
  • Experimental Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Modulation of the resistance of tumors offers new strategies to improve the therapeutical treatment of cancer. In this report, the anti-oestrogen tamoxifen was investigated in multidrug-resistant tumor cells in vitro and in vivo. The doxorubicin-resistance of L 1210/DOX-tumor cells, which express the multidrug-resistance phenotype, could be completely circumvented by addition of 1 μg/ml tamoxifen. In contrast, no increased effect could be observed in the parental L 1210 tumor cells or in cytosine arabinoside-resistant L 1210 cells not expressing the multidrug-resistance phenotype. Thus, the enhancing effect of tamoxifen was restricted only to the multidrug-resistant L 1210/DOX tumor cells. Similar to the in vitro experiments, a significant reduction in the growth in solid tumors of mice by the combined treatment of doxorubicin and tamoxifen was again observed only in the multidrug-resistant L 1210/DOX tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B, Andreeff M (1991) Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77:818–825

    PubMed  Google Scholar 

  • Cazin JL, Gosselin P, Cappelaere P, Robert J, Demaille A (1992) Drug resistance in oncology: from concepts to applications. J Cancer Res Clin Oncol 119:76–86

    PubMed  Google Scholar 

  • Chabner BA, Wilson W (1991) Reversal of multidrug resistance. J Clin Oncol 9:4–6

    PubMed  Google Scholar 

  • Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415–424

    PubMed  Google Scholar 

  • Efferth T, Löhrke H, Volm M (1989) Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 9:1633–1638

    PubMed  Google Scholar 

  • Efferth T, Volm M (1993) Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Lett 70:197–202

    PubMed  Google Scholar 

  • Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, Jones A (1990) Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer 65:1895–1902

    PubMed  Google Scholar 

  • Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199

    PubMed  Google Scholar 

  • Inaba M, Kobayashi H, Sakurai Y, Johnson RH (1979) Active efflux of daunomycin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 39:2200–2203

    PubMed  Google Scholar 

  • Kaye SB (1988) The multidrug resistance phenotype. Br J Cancer 58:691–694

    PubMed  Google Scholar 

  • Kirk J, Houlbrook S, Stuart NSA, Stratford IJ, Harris AL, Carmichael J (1993) Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 67:1189–1195

    PubMed  Google Scholar 

  • Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17–24

    PubMed  Google Scholar 

  • Murren JR, Hait WN (1992) Why haven't we cured multidrug-resistant tumors? Oncol Res 4:1–6

    PubMed  Google Scholar 

  • Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641–647

    PubMed  Google Scholar 

  • Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT (1989) Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug-resistance. Proc Natl Acad Sci USA 86:5128–5132

    PubMed  Google Scholar 

  • Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Piezia P, Miller TP, Salmon SE (1991) Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J NCI 83:105–110

    Google Scholar 

  • Pommerenke EW, Osswald H, Hahn EW, Volm M (1990) Activity of various amphiphilic agents in reversing multidrug resistance in L 1210 cells. Cancer Lett 55:17–23

    PubMed  Google Scholar 

  • Presant CA, Kennedy PS, Wiseman C, Gala K, Bouzaglou A, Wyres M, Naessig V (1986) Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Clin Oncol 9:355–357

    PubMed  Google Scholar 

  • Roninson IB (1992) The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43:95–102

    PubMed  Google Scholar 

  • Stewart DJ, Evans WK (1989) Non-chemotherapeutic agents that potentiate chemotherapy efficacy. Cancer Treat Rev 16:1–40

    Google Scholar 

  • Stuart NSA, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J (1992) High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br J Cancer 66:833–839

    PubMed  Google Scholar 

  • Symes MO (1993) Multi-drug resistance due to P-glycoprotein (Review). Int J Oncol 3:539–542

    Google Scholar 

  • Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan C, Fine RL (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. JNCI 84:1811–1816

    PubMed  Google Scholar 

  • Volm M, Maas E, Mattern J (1980) Detection of induced resistance to cytosine-arabinoside with a short-term test. Eur J Cancer 16:733–736

    PubMed  Google Scholar 

  • Volm M, Mattern J, Samsel B (1992) Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-π in human lung tumors. Cancer 70:764–769

    PubMed  Google Scholar 

  • Volm M, Wayss K, Kaufmann M, Mattern J (1979) Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 15:983–993

    PubMed  Google Scholar 

  • Volm M, Bak M, Efferth T, Mattern J (1989) Induced multidrug resistance in murine leukemia L 1210 and associated changes in surface membrane glycoprotein. J Cancer Res Clin Oncol 115:17–24

    PubMed  Google Scholar 

  • Volm M, Pommerenke EW, Efferth T, Löhrke H, Mattern J (1991) Circumvention of multidrug-resistance in human kidney and kidney carcinoma in vitro. Cancer 67:2484–2489

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. German Cancer Research Center (0511), P.O. Box 10 19 49, W-69009, Heidelberg, Germany

    Elke Pommerenke, Jürgen Mattern & Manfred Volm

Authors
  1. Elke Pommerenke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürgen Mattern
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manfred Volm
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pommerenke, E., Mattern, J. & Volm, M. Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo. J Cancer Res Clin Oncol 120, 422–426 (1994). https://doi.org/10.1007/BF01240142

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01240142

Key words

Search

Navigation